Skip to main content Skip to secondary navigation

in vitro Models

Main content start

in vitro Disease Modeling and Functionality Assessment

Human-Relevant Models to Accelerate Drug Discovery

We design advanced, physiologically relevant in vitro disease models to support mechanism studies, target validation, and early-stage drug discovery. By leveraging iPSC-derived cells, primary cells, and engineered cell systems, we translate complex disease biology into actionable, decision-grade assays.

Why Partner With Us?

  • Reliability: Reproducible systems delivering consistent, high-quality data.
  • Physiological Relevance: Models that mimic human disease biology, enhancing clinical translatability.
  • Custom Solutions: Tailored to your specific research needs, from genetic backgrounds to disease phenotypes.

Our Toolkit: Advanced Cell Systems

We select the optimal cell platform to address your scientific question:

iPSC-Derived Cells

  • Generate virtually unlimited quantities of disease-relevant human cells (e.g., neurons, cardiomyocytes).
  • Create patient-specific models by reprogramming cells from individuals with target diseases.

Primary Cells

  • Gold-standard biological relevance: Directly sourced from human/animal tissues.
  • Ideal for validating cell function and disease mechanisms in their natural state.

Engineered Cell Systems

  • CRISPR-Cas9 gene editing: Introduce, remove, or correct genes to establish causal links between genetic changes and disease.
  • Isogenic pairs: Compare cells with/without a specific genetic alteration to isolate disease mechanisms.

Applications: Accelerating Early-Stage R&D

Mechanism of Action (MoA) Studies

  • Uncover how and why diseases develop at cellular/molecular levels.
  • Map biological pathways to identify therapeutic intervention points.

Target Validation

  • Confirm the therapeutic potential of genes or proteins.
  • Demonstrate that modulating a target produces the desired biological effect.

Drug Screening & Development

  • Test the efficacytoxicity, and potency of candidate gene therapy products in a highly relevant biological system.
  • Enable high-throughput screening to rapidly identify lead candidates.